Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

NCT05113771 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT05113771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2022
Completion date
March 5, 2024
Enrollment
197 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression